Physical Activity, Proliferation and Immune Markers in Benign Breast Tissue

Sponsor
Dana-Farber Cancer Institute (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03657628
Collaborator
National Cancer Institute (NCI) (NIH)
60
1
1
71.5
0.8

Study Details

Study Description

Brief Summary

This research study is evaluating the effect of exercise on markers in breast tissue and blood of premenopausal women who have been found to have dense breast tissue on mammogram.

Condition or Disease Intervention/Treatment Phase
  • Other: Exercise Intervention
N/A

Detailed Description

Women who exercise regularly have a lower risk of developing breast cancer, but the processes through which exercise could make cancer less likely to occur are not known. Some research in animals has shown that exercise can slow the growth of breast cancer cells and may increase the body's own defense mechanisms by stimulating the immune system. Very little is known about the effects of exercise on breast tissue in people. Understanding what changes occur in breast tissue and related markers in blood when a woman begins to exercise could provide more information about the ways in which exercise could prevent breast cancer.

The study is designed to look at the changes that occur in markers found in breast tissue and blood in women with dense breast tissue who take part in an exercise program. Density of breast tissue is a measure of how much of the breast tissue is made up of cells rather than fat. Breast density on mammogram has been linked to the risk of developing breast cancer, with women with higher degrees of breast density having a higher risk of developing breast cancer compared to women whose breasts are less dense.

Since the investigators do not know if these blood or breast tissue tests have any relationship to the development of breast cancer, the investigators do not plan to share the results of these tests with the participant or its physician. The investigators will give the participants the option of receiving the overall study results when the trial is completed, if the participant would like to receive them.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Pilot Study of the Impact of a Physical Activity Intervention on Proliferation and Immune Markers in Benign Breast Tissue in Women With High Mammographic Breast Density
Actual Study Start Date :
Sep 17, 2018
Anticipated Primary Completion Date :
Aug 31, 2023
Anticipated Study Completion Date :
Aug 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Physical activity

The exercise intervention will consist of a supervised, moderate-intensity aerobic exercise program. Will receive social/behavioral support Will receive research staff contact time to encourage them to increase their physical activity level The participants will be given the option of a third supervised session each week

Other: Exercise Intervention
Strength training and moderate-intensity, aerobic exercise

Outcome Measures

Primary Outcome Measures

  1. Impact of exercise upon expression of Ki-67 [12-weeks]

    To evaluate the change in breast tissue expression of Ki-67 in premenopausal women with increased breast density taking part in a 12-week physical activity intervention

Secondary Outcome Measures

  1. Changes in biomarker (IL-6) [12-weeks]

  2. Changes in biomarker (TNF-a) [12-weeks]

  3. Changes in biomarker (CRP) [12-weeks]

  4. Changes in minutes of weekly physical activity [12-weeks]

    7-Day Physical Activity Recall Interview

  5. Changes in waist to hip ratio [12-weeks]

  6. Changes in weight (% change) [12-weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Written informed consent prior to any study-related procedures

  • Premenopausal women, defined as:

  • having regular menstrual cycles

  • age ≤ 50 years with an intact IUD

  • history of hysterectomy without oophorectomy

  • Heterogeneously dense or very dense (BIRADS 3 or 4) breast tissue on mammogram within the last 3 years

  • Physically inactive; engaging in <90 minutes of moderate or vigorous intensity PA per week

  • No prior history of breast cancer

  • At least 18 years old

  • Physically able to exercise

  • English speaking and able to read English

Exclusion Criteria:
  • Self-reported inability to walk 2 blocks (at any pace)

  • Prior history of breast cancer; prior DCIS is allowable as long as participant is not taking endocrine therapy and has at least 1 breast that has not been irradiated.

  • On oral contraceptives; Mirena IUD is acceptable

  • Cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity. Examples would include unstable angina, recent myocardial infarction, oxygen-dependent pulmonary disease, and osteoarthritis requiring imminent joint replacement. Moderate arthritis that does not preclude physical activity is not a reason for ineligibility.

  • Psychiatric disorders or conditions that would preclude participation in the study intervention (e.g. untreated major depression or psychosis, substance abuse, severe personality disorder)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Dana Farber Cancer Institute Boston Massachusetts United States 02215

Sponsors and Collaborators

  • Dana-Farber Cancer Institute
  • National Cancer Institute (NCI)

Investigators

  • Principal Investigator: Jennifer Ligibel, MD, Dana-Farber Cancer Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jennifer A. Ligibel, MD, Principal Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT03657628
Other Study ID Numbers:
  • 18-168
  • 1P50CA168504-05
First Posted:
Sep 5, 2018
Last Update Posted:
Jan 6, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jennifer A. Ligibel, MD, Principal Investigator, Dana-Farber Cancer Institute
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 6, 2022